Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17140992 | 0.90 | ENPP2 (0.38) | CYP1A2CYP2C19 | |
| SCHEMBL17140968 | 0.88 | ME2 (0.33) | — | |
| SCHEMBL18940712 | 0.87 | ENPP2 (0.30) | — | |
| SCHEMBL17140959 | 0.86 | ITGB3 (0.35) | ITGB3ITGA2B | |
| SCHEMBL17140987 | 0.86 | ALDH1A1 (0.41) | CYP2C9TSHRCYP2D6CYP3A4HIF1A | |
| SCHEMBL17141087 | 0.85 | ITGAL (0.36) | CYP2C9TSHRCYP2D6CYP3A4CYP1A2 | |
| SCHEMBL17141123 | 0.85 | CHRM4 (0.37) | — | |
| SCHEMBL17140628 | 0.84 | ALDH1A1 (0.35) | SMN1; SMN2 | |
| SCHEMBL17140871 | 0.84 | MAPT (0.37) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17140941 | 0.84 | ENPP2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | CYP2C9 2458/4885TSHR 3195/4885CYP2D6 1228/4885 |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | CYP2C9 2458/4885TSHR 3195/4885CYP2D6 1228/4885 |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, SLC10A1, CXCR3 | CYP2C9 2458/4885TSHR 3195/4885CYP2D6 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.